Information Provided By:
Fly News Breaks for August 7, 2018
BMRN
Aug 7, 2018 | 07:55 EDT
Stifel transferred coverage of BioMarin to analyst Paul Matteis, who set a Buy rating and $114 price target on the shares. He sees the approved product base having a path to about $2B in 2019 revenue, which provides a share floor of about $80 ahead of a handful of clinical catalysts during the next 12-18 months, Matteis tells investors. BioMarin is better positioned than most mature biotechs in terms of drug pricing pressure and competition risk, added the analyst.
News For BMRN From the Last 2 Days
There are no results for your query BMRN